Tela Bio Inc (TELA) - Total Liabilities
Based on the latest financial reports, Tela Bio Inc (TELA) has total liabilities worth $75.09 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Tela Bio Inc (TELA) equity growth momentum to track the company's year-over-year net asset growth rate.
Tela Bio Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Tela Bio Inc's total liabilities have evolved over time, based on quarterly financial data.
Tela Bio Inc Competitors by Total Liabilities
The table below lists competitors of Tela Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Globus Maritime Ltd
NASDAQ:GLBS
|
USA | $116.02 Million |
|
Nath Bio-Genes (India) Limited
NSE:NATHBIOGEN
|
India | Rs4.17 Billion |
|
Globon Co. Ltd
KQ:019660
|
Korea | ₩9.65 Billion |
|
P3 Health Partners Inc
NASDAQ:PIII
|
USA | $807.32 Million |
|
Kekrops S.A.
AT:KEKR
|
Greece | €5.38 Million |
|
Beauty Community Public Company Limited
BK:BEAUTY
|
Thailand | ฿81.31 Million |
|
Ymc Co. Ltd
KQ:155650
|
Korea | ₩55.40 Billion |
|
Stampede Drilling Inc
V:SDI
|
Canada | CA$31.79 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Tela Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TELA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -14.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tela Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tela Bio Inc (2017–2025)
The table below shows the annual total liabilities of Tela Bio Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $75.11 Million | +27.58% |
| 2024-12-31 | $58.87 Million | -0.51% |
| 2023-12-31 | $59.17 Million | +10.49% |
| 2022-12-31 | $53.55 Million | +26.16% |
| 2021-12-31 | $42.45 Million | +13.39% |
| 2020-12-31 | $37.43 Million | +1.28% |
| 2019-12-31 | $36.96 Million | -77.61% |
| 2018-12-31 | $165.09 Million | +33.45% |
| 2017-12-31 | $123.70 Million | -- |
About Tela Bio Inc
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue… Read more